The GLP-1 receptor agonist market is by drug class into, liraglutide, semaglutide, tirzepatide, dulaglutide and other drugs
Many of the neuroprotective, neurodegenerative, psychiatric, and addiction-related applications discussed remain investigational, and no GLP-1 receptor agonist is currently approved by regulatory authorities for the treatment or prevention of Alzheimers disease, Parkinsons disease, depression, substance use disorders, or other neurological indications unless specifically stated otherwise
Treasury bonds and bills
The GLP-1 RAs appear to modify atherosclerosis in the arteries, much like statin medications that treat cholesterol, and takes about a year or more to demonstrate measurable benefits on risk for cardiovascular events, whereas the SGLT2i medications seem to affect heart and kidney function more prominently and faster, with benefits evident very soon after starting the medication
MarcangeliVYoussefLDulacMCarvalhoLPHajj-BoutrosGReynaudOet al
Sermorelin therapy is indicated only for individuals with demonstrated need (such as GH deficiency)
